Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CGEM | 8-K | bullish | 7/10 | Cullinan Therapeutics reported Q2 2026 EPS of -$0.81, beating consensus of -$0.85 by 4.9%, while net loss narrowed to $5 | Aug 6, 2026 |
| ZTS | 8-K | bearish | 7/10 | Zoetis reported Q2 2026 adjusted EPS of $1.87, a 1% beat vs. $1.85 consensus, but revenue of $2.468B slightly missed the | Aug 6, 2026 |
| SRRK | 8-K | neutral | 5/10 | Scholar Rock reported Q2 2026 results in line with consensus: EPS of -$0.84 (0.3% beat vs -$0.84 consensus) and zero rev | Aug 6, 2026 |
| IRWD | 8-K | bullish | 7/10 | Ironwood Pharmaceuticals reported Q2 2026 GAAP EPS of $0.31, beating the $0.28 consensus by 10.7%, on revenue of $113.0M | Aug 6, 2026 |
| SION | 8-K | neutral | 4/10 | Sionna Therapeutics reported Q2 2026 financial results with a net loss of $29.9M ($-0.66/share), wider than the $18.1M l | Aug 6, 2026 |
| RGNX | 8-K | bullish | 7/10 | REGENXBIO reported Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus of -$0.11, driven by a $100M AbbVie milest | Aug 6, 2026 |
| XERS | 8-K | bullish | 7/10 | Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and net product revenue of $91.0M (+34% YoY), driven | Aug 6, 2026 |
| ACRS | 8-K | neutral | 4/10 | Aclaris Therapeutics reported Q2 2026 net loss of $21.5M ($-0.15/share) on revenue of $1.6M, slightly better than consen | Aug 6, 2026 |
| ROIV | 8-K | neutral | 4/10 | Roivant reported Q1 FY2026 results with a net loss of $0.26 per share, slightly narrower than the $0.33 loss in the prio | Aug 6, 2026 |
| IMVT | 8-K | bearish | 6/10 | Immunovant reported a Q1 FY2027 net loss of $153.2M ($-0.75/share), which was a 22.2% miss vs the $-0.61 consensus estim | Aug 6, 2026 |
| HROW | 8-K | bullish | 7/10 | Harrow has entered into a definitive agreement to acquire global rights to TYRVAYA (varenicline solution) nasal spray fr | Aug 6, 2026 |
| DTIL | 8-K | bullish | 7/10 | Precision BioSciences reported Q2 2026 results with no revenue and a GAAP net loss of $32.7M ($1.26/share), a wider loss | Aug 6, 2026 |
| TARS | 8-K | mixed | 6/10 | Tarsus reported Q2 2026 product sales of $173.9M (+69% YoY) and raised full-year XDEMVY guidance to $685-705M, but EPS o | Aug 6, 2026 |
| GHRS | 6-K | bullish | 7/10 | GH Research reported Q2 2026 financial results with a net loss of $15.1 million ($0.23 per share), widening from a $9.3 | Aug 6, 2026 |
| NUVB | 8-K | mixed | 5/10 | Nuvation Bio reported Q2 2026 total revenue of $31.7M, including $23.2M in IBTROZI product revenue (25% QoQ growth), but | Aug 6, 2026 |
| CMPX | 8-K | bullish | 7/10 | Compass Therapeutics reported Q2 2026 results with a net loss of $0.13 per share, slightly better than the $0.14 loss in | Aug 6, 2026 |
| BIVI | 8-K | bullish | 7/10 | BioVie announced positive topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson's disease. | Aug 6, 2026 |
| BIVI | S-1/A | bearish | 7/10 | BioVie filed Amendment No. 2 to its S-1 registration statement for a best-efforts offering of up to 56.4 million shares | Aug 6, 2026 |
| CRLBF | 6-K | mixed | 6/10 | Cresco Labs reported Q2 2026 revenue of $173.3M (+5.9% YoY) and net income of $15.4M, swinging from a -$13.9M loss in Q2 | Aug 6, 2026 |
| IFRX | 6-K | neutral | 5/10 | InflaRx reported H1 2026 results with a net loss of €16.2M (improved from €22.7M YoY) and zero revenue after discontinui | Aug 6, 2026 |
| MIRA | 8-K | neutral | 4/10 | MIRA Pharmaceuticals reported positive toxicokinetic findings from a 7-day repeated-dose study of its obesity drug candi | Aug 6, 2026 |
| ICLR | 6-K | bullish | 6/10 | ICON plc priced $2.15 billion of senior unsecured notes via its subsidiary, with proceeds earmarked to repay its bridge | Aug 6, 2026 |
| AUPH | 8-K | bullish | 6/10 | Aurinia Pharmaceuticals reported Q2 2026 revenue of $83.2M (+19% YoY) and diluted EPS of $0.28 (+75% YoY), both exceedin | Aug 6, 2026 |
| NVAX | 8-K | neutral | 5/10 | Novavax reported Q2 2026 total revenue of $57M, a 76% decline YoY from $239M, driven by the absence of a $175M BLA miles | Aug 6, 2026 |
| PRME | 8-K | bullish | 6/10 | Prime Medicine reported Q2 2026 EPS of -$0.24, beating consensus of -$0.26 by 7.7%, with collaboration revenue of $1.154 | Aug 6, 2026 |
| MBX | 8-K | bullish | 7/10 | MBX Biosciences reported Q2 2026 results with a net loss of $0.78 per share, significantly missing the consensus estimat | Aug 6, 2026 |
| VIVS | 8-K | mixed | 6/10 | VivoSim Labs filed an 8-K announcing it regained Nasdaq compliance (Rule 5550(b)(1) minimum equity), reported ~$10.1M ca | Aug 6, 2026 |
| ALXO | 8-K | neutral | 4/10 | ALX Oncology reported Q2 2026 results with a GAAP net loss of ($0.13) per share, beating consensus estimates of ($0.16) | Aug 6, 2026 |
| EWTX | 8-K | mixed | 7/10 | Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12.2% miss vs consensus of $-0.47, with no revenue. Th | Aug 6, 2026 |
| WHWK | 8-K | neutral | 3/10 | Whitehawk Therapeutics reported Q2 2026 results with a net loss of $16.6M ($-0.20 EPS), narrower than the $52.6M loss in | Aug 6, 2026 |